TY - JOUR
T1 - 3D Printing Pharmaceuticals
T2 - Drug Development to Frontline Care
AU - Trenfield, Sarah J.
AU - Awad, Atheer
AU - Goyanes, Alvaro
AU - Gaisford, Simon
AU - Basit, Abdul W.
N1 - Funding Information:
The authors would like to thank Martin Rowland for his review of the manuscript and contribution of additional industrial perspectives. The authors thank the Engineering and Physical Sciences Research Council (EPSRC), UK for their financial support ( EP/L01646X ).
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/5
Y1 - 2018/5
N2 - 3D printing (3DP) is forecast to be a highly revolutionary technology within the pharmaceutical sector. In particular, the main benefits of 3DP lie in the production of small batches of medicines, each with tailored dosages, shapes, sizes and release characteristics. The manufacture of medicines in this way may finally lead to the concept of personalised medicines becoming a reality. In the shorter term, 3DP could be extended throughout the drug development process, ranging from preclinical development and clinical trials, through to frontline medical care. In this review, we provide a timely perspective on the motivations and potential applications of 3DP pharmaceuticals, as well as a practical viewpoint on how 3DP could be integrated across the pharmaceutical space.
AB - 3D printing (3DP) is forecast to be a highly revolutionary technology within the pharmaceutical sector. In particular, the main benefits of 3DP lie in the production of small batches of medicines, each with tailored dosages, shapes, sizes and release characteristics. The manufacture of medicines in this way may finally lead to the concept of personalised medicines becoming a reality. In the shorter term, 3DP could be extended throughout the drug development process, ranging from preclinical development and clinical trials, through to frontline medical care. In this review, we provide a timely perspective on the motivations and potential applications of 3DP pharmaceuticals, as well as a practical viewpoint on how 3DP could be integrated across the pharmaceutical space.
KW - additive manufacturing
KW - clinical trials
KW - drug development
KW - first-in-human
KW - personalised medicines
KW - three-dimensional printing
UR - http://www.scopus.com/inward/record.url?scp=85042384351&partnerID=8YFLogxK
U2 - 10.1016/j.tips.2018.02.006
DO - 10.1016/j.tips.2018.02.006
M3 - Review article
C2 - 29534837
AN - SCOPUS:85042384351
SN - 0165-6147
VL - 39
SP - 440
EP - 451
JO - Trends in Pharmacological Sciences
JF - Trends in Pharmacological Sciences
IS - 5
ER -